Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera鈥檚 genomic jargon isn鈥檛 easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you鈥檝e ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. AG真人官方-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place鈥�Natera SEC filings explained simply. Common questions such as 鈥淗ow do I find the latest Natera proxy statement executive compensation?鈥� or 鈥淲here is the Natera 8-K material events explained?鈥� are answered inside every filing card.
Our platform doesn鈥檛 stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you鈥檙e a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera鈥檚 dense disclosures into actionable insight鈥攏o genetics PhD required.
Natera, Inc. (NTRA) 鈥� Form 4 filing
CFO Michael Burkes Brophy reported a routine set of transactions tied to RSU vesting and a previously adopted Rule 10b5-1 plan.
- RSU conversion: On 22 Jul 2025, 1,250 restricted stock units vested and were converted to common shares (Code M).
- Share sales: The executive sold 2,170 shares across four trades on 22-24 Jul at weighted-average prices of $139.20-$141.28 to cover tax-withholding and liquidity needs.
- Net change: Beneficial ownership fell by 1,250 shares, leaving Brophy with 70,494 common shares (<鈮�1.8% reduction) and 1,250 unvested RSUs.
- Plan status: All dispositions were executed under a 10b5-1 plan adopted 14 Jun 2024, limiting discretionary timing.
No other corporate events or material financial information are disclosed in this filing.
Shimmick Corp. (SHIM) 鈥� Form 144 filing discloses that insider Mitchell B. Goldsteen plans to sell up to 3,900 common shares through TD Securities on or about 24 Jul 2025. At the most recent market price used in the filing, the sale would raise roughly $8.1 k. The proposed shares represent less than 0.01 % of the company鈥檚 34.36 m shares outstanding.
The notice also lists an extensive series of prior open-market sales by Goldsteen during the past three months. Adding the individual transactions shown, the insider has already disposed of 鈮�252 k shares, generating cumulative gross proceeds of several hundred thousand dollars. The new 3,900-share lot suggests continued selling momentum.
No financial performance data, corporate events or explanatory remarks accompany the filing; Form 144 only signals a potential disposition. Investors typically view persistent insider selling鈥攑articularly at this scale鈥攁s a bearish sentiment indicator, although the absolute percentages remain small relative to total shares outstanding.
Millennium Management LLC and affiliates filed a Schedule 13G disclosing a passive stake in AngioDynamics, Inc. (ANGO). As of 16 Jul 2025 the group beneficially owns between 2.12 M and 2.15 M common shares, equal to ~5.2-5.3 % of the outstanding stock. All voting and dispositive power is reported as shared; no sole authority exists.
The filing covers four reporting persons 鈥� Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and founder Israel A. Englander. Each entity is organized in Delaware (Englander is a U.S. citizen) and the shares are held through investment vehicles controlled by Millennium. The group certifies the position was acquired solely for investment purposes and not to influence control of the issuer.
Crossing the 5 % ownership threshold on 07/16/25 triggered the disclosure; a joint filing agreement dated 21 Jul 2025 is included. No purchase prices or additional transaction details are provided.
JPMorgan Chase & Co. filed Amendment No. 2 to Schedule 13G on 22 Jul 2025, reporting a passive ownership position in MGIC Investment Corp. (MTG) as of 30 Jun 2025.
The banking group beneficially owns 18,111,064 common shares, equal to 7.6 % of MTG鈥檚 outstanding stock. It holds sole voting power over 16,927,029 shares and sole dispositive power over 18,072,928 shares; only 12,463 shares carry shared dispositive power, and none carry shared voting power.
The stake is held 鈥渋n the ordinary course of business鈥� under Rule 13d-1(b), with JPMorgan classified as a parent holding company (HC). Subsidiaries involved include J.P. Morgan Securities LLC, JPMorgan Chase Bank N.A., and others. The disclosure meets the >5 % threshold but contains no intent to influence control.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What core services does Natera Inc offer?
How does Natera ensure accuracy in its testing processes?
What is non-invasive prenatal testing (NIPT) and how does Natera apply it?
What role does bioinformatics play in Natera's diagnostic solutions?
How does Natera address the needs of oncology patients?
In what ways does Natera contribute to the field of genetic diagnostics?
How is Natera positioned within the competitive landscape of diagnostic companies?
